Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

被引：4

作者：

Quintela-Fandino, Miguel

Apala, Juan V.

Salgado, Alfonso Cortes

Mouron, Silvana Andrea

Guerra, Juan Antonio

Cortes, Mana Gion

Morente, Manuel

Manso, Luis

机构：

[1] CNIO Spanish Natl Canc Res Ctr, Madrid, Spain

[2] CNIO, Madrid, Spain

[3] Hosp Ramon & Cajal, Madrid, Spain

[4] Spanish Natl Canc Res CNIO, Breast Canc Clin Res Unit, Madrid, Spain

[5] Hosp Fuenlabrada, Madrid, Spain

[6] Hosp 12 Octubre, Madrid, Spain

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2552

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2552

引用

页数：2